Remy Luthringer - Minerva Neurosciences President
| NERV Stock | USD 2.26 0.00 0.00% |
President
Dr. Remy Luthringer Ph.D. is Executive Chairman of the Board, Chief Executive Officer of the of Minerva Neurosciences, Inc. effective November 20, 2014 . He has provided services to us since July 2010, first as a consultant and then as an employee beginning in May 2014. Dr. Luthringer was named our President and Chief Executive Officer in November 2014, and served as President until December 2017. He has served on our Board since November 2014 since 2018.
| Age | 63 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 1500 District Avenue, Burlington, MA, United States, 01803 |
| Phone | 617 600 7373 |
| Web | https://www.minervaneurosciences.com |
Latest Insider Transactions
Luthringer serves as an advisor to Medicxi Ventures, formerly Index Ventures Life Sciences, and previously served as an advisor to Index Ventures and as Chief Medical Officer to Index Life VI, a biotechnology fund raised by Index Ventures. He received his Ph.D. in Pharmacology and Neurosciences from University Louis Pasteur . Our Board believes that Dr. Luthringer should serve on our Board due to his extensive knowledge of our business as well as his corporate vision and operational knowledge, which provide strategic guidance to our Board.Remy Luthringer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Remy Luthringer against Minerva Neurosciences stock is an integral part of due diligence when investing in Minerva Neurosciences. Remy Luthringer insider activity provides valuable insight into whether Minerva Neurosciences is net buyers or sellers over its current business cycle. Note, Minerva Neurosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Minerva Neurosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Remy Luthringer over six months ago Disposition of 18750 shares by Remy Luthringer of Minerva Neurosciences subject to Rule 16b-3 |
Minerva Neurosciences Management Efficiency
The company has return on total asset (ROA) of (0.2891) % which means that it has lost $0.2891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7509) %, meaning that it created substantial loss on money invested by shareholders. Minerva Neurosciences' management efficiency ratios could be used to measure how well Minerva Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 1.11 in 2024, whereas Return On Tangible Assets are likely to drop (0.75) in 2024. At this time, Minerva Neurosciences' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 52.9 M in 2024, whereas Other Assets are likely to drop slightly above 1.3 M in 2024.Similar Executives
| Found 7 records | PRESIDENT Age | ||
| Erin MD | Terns Pharmaceuticals | 53 | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Robert Lisicki | Zura Bio Limited | 57 | |
| Gwendolyn Binder | Cabaletta Bio | 49 | |
| Hong Liang | Kodiak Sciences | 52 | |
| Anna Kluczewska | Eyepoint Pharmaceuticals | N/A | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -6.75 | ||||
| Return On Asset | -0.29 |
Minerva Neurosciences Leadership Team
Elected by the shareholders, the Minerva Neurosciences' board of directors comprises two types of representatives: Minerva Neurosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Minerva. The board's role is to monitor Minerva Neurosciences' management team and ensure that shareholders' interests are well served. Minerva Neurosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Minerva Neurosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO VP | ||
| Ramana Kuchibhatla, Senior Development | ||
| MBA FCMA, President | ||
| Remy Luthringer, Executive Vice President and Head of Research & Development (R&D) | ||
| FCMA FCMA, President | ||
| William Boni, Vice Communications | ||
| Joseph Reilly, COO and Sr. VP | ||
| Frederick CPA, CFO VP | ||
| Pr MD, Chief Officer |
Minerva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Minerva Neurosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.75 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (11.49 M) | ||||
| Shares Outstanding | 6.99 M | ||||
| Shares Owned By Insiders | 22.26 % | ||||
| Shares Owned By Institutions | 30.47 % | ||||
| Number Of Shares Shorted | 23.38 K | ||||
| Price To Earning | 69.58 X | ||||
| Price To Book | 2.68 X | ||||
| Price To Sales | 1.87 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.